Appointment of Chief Financial Officer

RNS Number : 1045Q

Venn Life Sciences Holdings PLC

15 June 2015

 

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

Appointment of Chief Financial Officer

On 12 May 2015, Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announced the appointment of Jonathan Hartshorn as Chief Financial Officer with effect from 15th June 2015.

The Company is pleased to confirm that Jonathan will begin his duties in that role today.

The Company reaffirms that save as disclosed in the announcement of 12 May 2015, there are no other disclosures required in relation to paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Enquiries:

Venn Life Sciences Holdings Plc	www.vennlifesciences.com
Tony Richardson, Chief Executive Officer	Tel: [phone]
Orla Mc Guinness, Marketing Manager	Tel: [phone]
Zeus Capital (Nominated Adviser and Broker)
Ross Andrews/Andrew Jones	Tel: [phone]
Alex Davies	Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 

END

 

 

MSCBIGDLCUBBGUS